4.7 Article

Episodic ataxia type 1: clinical characterization, quality of life and genotype-phenotype correlation

Journal

BRAIN
Volume 137, Issue -, Pages 1009-1018

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/brain/awu012

Keywords

episodic ataxia type 1 (EA1); KCNA1; quality of life

Funding

  1. National Institutes of Health [2U54NS059065]
  2. University of Kansas Medical Center [UL1TR000001 NCATS/NIH]
  3. University of Rochester [UL1 RR 024160 NCRR/NIH]
  4. MRC Centre [MRC Centre for Neuromuscular Diseases Centre] [G0601943]
  5. UCLH NIHR Biomedical Research Centre
  6. MRC [G0601943, MR/K000608/1] Funding Source: UKRI
  7. Medical Research Council [G0601943, MR/K000608/1] Funding Source: researchfish

Ask authors/readers for more resources

Episodic ataxia type 1 is a rare autosomal dominant disorder that affects the cerebellum and peripheral nerves. In a cross-sectional, prospective study, Graves et al. describe clinical features of patients with and without mutations in the KCN1A gene, and suggest possible outcome measures for use in clinical trials.Episodic ataxia type 1 is considered a rare neuronal ion channel disorder characterized by brief attacks of unsteadiness and dizziness with persistent myokymia. To characterize the natural history, develop outcome measures for future clinical trials, and correlate genotype with phenotype, we undertook an international, prospective, cross-sectional study. Thirty-nine individuals (51% male) were enrolled: median age 37 years (range 15-65 years). We identified 10 different pathogenic point mutations in KCNA1 that accounted for the genetic basis of 85% of the cohort. Participants with KCNA1 mutations were more likely to have a positive family history. Analysis of the total cohort showed that the first episode of ataxia occurred before age 20 in all but one patient, with an average age of onset of 7.9 years. Physical exertion, emotional stress and environmental temperature were the most common triggers for attacks. Attack frequency ranged from daily to monthly, even with the same KCNA1 genotype. Average attack duration was in the order of minutes. Ten participants (26%) developed permanent cerebellar signs, which were related to disease duration. The average Scale for the Assessment and Rating of Ataxia score (SARA, a standardized measure of cerebellar dysfunction on clinical examination, scores range from 0-40) was an average of 3.15 for all participants (range 0-14), but was only 2 in those with isolated episodic ataxia compared with 7.7 in those with progressive cerebellar ataxia in addition to episodic ataxia. Thirty-seven participants completed the SF-36, a quality of life survey; all eight domain norm-based average scores (mean = 50) were below normal with mental health being the lowest (41.3) in those with mutation positive episodic ataxia type 1. Scores on SF-36 correlated negatively with attack frequency. Of the 39 participants in the study, 33 harboured mutations in KCNA1 whereas the remaining six had no mutation identified. Episodic ataxia type 1 phenocopies have not been described previously and we report their clinical features, which appear to be different to those with a KCNA1 mutation. This large prospective study of both genetically confirmed episodic ataxia type 1 and episodic ataxia type 1 phenocopies provides detailed baseline characteristics of these disorders and their impact on participants. We found that attacks had a significant effect on quality of life. Unlike previous studies, we found that a significant number of individuals with genetically confirmed episodic ataxia type 1 (21%) had accumulated persistent cerebellar symptoms and signs. These data will enable the development of outcome measures for clinical trials of treatment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available